Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

The systems biology of neurofibromatosis type 1--critical roles for microRNA.

Lee MJ, Cho JH, Galas DJ, Wang K.

Exp Neurol. 2012 Jun;235(2):464-8. doi: 10.1016/j.expneurol.2011.10.023. Epub 2011 Oct 31. Review.

PMID:
22075182
2.

Neurofibromatosis type 1: pathology, clinical features and molecular genetics.

von Deimling A, Krone W, Menon AG.

Brain Pathol. 1995 Apr;5(2):153-62. Review.

PMID:
7670656
3.

MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1.

Chai G, Liu N, Ma J, Li H, Oblinger JL, Prahalad AK, Gong M, Chang LS, Wallace M, Muir D, Guha A, Phipps RJ, Hock JM, Yu X.

Cancer Sci. 2010 Sep;101(9):1997-2004. doi: 10.1111/j.1349-7006.2010.01616.x.

4.

Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.

Lau N, Feldkamp MM, Roncari L, Loehr AH, Shannon P, Gutmann DH, Guha A.

J Neuropathol Exp Neurol. 2000 Sep;59(9):759-67.

PMID:
11005256
5.

Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway.

Feldkamp MM, Angelov L, Guha A.

Surg Neurol. 1999 Feb;51(2):211-8.

PMID:
10029430
6.

Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1.

Klose A, Ahmadian MR, Schuelke M, Scheffzek K, Hoffmeyer S, Gewies A, Schmitz F, Kaufmann D, Peters H, Wittinghofer A, Nürnberg P.

Hum Mol Genet. 1998 Aug;7(8):1261-8.

PMID:
9668168
7.

[Molecular genetics of neurofibromatosis type 1].

Suzuki H, Takahashi K, Shibahara S.

Nihon Rinsho. 1993 Sep;51(9):2457-61. Review. Japanese.

PMID:
8411728
8.

Neurofibromatosis type 1: piecing the puzzle together.

Feldkamp MM, Gutmann DH, Guha A.

Can J Neurol Sci. 1998 Aug;25(3):181-91. Review.

PMID:
9706718
9.

Neurofibromatosis 1: closing the GAP between mice and men.

Dasgupta B, Gutmann DH.

Curr Opin Genet Dev. 2003 Feb;13(1):20-7. Review.

PMID:
12573431
10.

Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.

Yan N, Ricca C, Fletcher J, Glover T, Seizinger BR, Manne V.

Cancer Res. 1995 Aug 15;55(16):3569-75.

12.
13.

Developmental abnormalities and cancer predisposition in neurofibromatosis type 1.

Larizza L, Gervasini C, Natacci F, Riva P.

Curr Mol Med. 2009 Jun;9(5):634-53. Review.

PMID:
19601812
14.

Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.

Dilworth JT, Kraniak JM, Wojtkowiak JW, Gibbs RA, Borch RF, Tainsky MA, Reiners JJ Jr, Mattingly RR.

Biochem Pharmacol. 2006 Nov 30;72(11):1485-92. Epub 2006 Apr 28. Review.

PMID:
16797490
15.

Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1).

Schindeler A, Little DG.

Bone. 2008 Apr;42(4):616-22. doi: 10.1016/j.bone.2007.11.006. Epub 2007 Nov 28. Review.

PMID:
18248783
16.

The neurofibromatoses: when less is more.

Gutmann DH.

Hum Mol Genet. 2001 Apr;10(7):747-55. Review.

PMID:
11257108
17.

Molecular, genetic, and cellular pathogenesis of neurofibromas and surgical implications.

Gottfried ON, Viskochil DH, Fults DW, Couldwell WT.

Neurosurgery. 2006 Jan;58(1):1-16; discussion 1-16. Review.

PMID:
16385324
18.

Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.

Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K.

Nat Genet. 1996 Feb;12(2):144-8.

PMID:
8563751
19.

Ras-GTP regulation is not altered in cultured melanocytes with reduced levels of neurofibromin derived from patients with neurofibromatosis 1 (NF1).

Griesser J, Kaufmann D, Eisenbarth I, Bäuerle C, Krone W.

Biol Chem Hoppe Seyler. 1995 Feb;376(2):91-101.

PMID:
7794530
20.

Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-/- cells.

Hiatt KK, Ingram DA, Zhang Y, Bollag G, Clapp DW.

J Biol Chem. 2001 Mar 9;276(10):7240-5. Epub 2000 Nov 15.

Supplemental Content

Support Center